| Company/Division name | Par Sterile Products LLC |
| Parent company | Endo International PLC |
| Type of work | Manufacturing |
| Reshoring category: | Foreign Direct Investment |
| Year reshoring announced: | 2021 |
| Domestically, the work will be done: | In-house |
| Capital investment ($): | 120 |
| Country(ies) from which reshored: | Ireland |
| City reshored to: | Rochester |
| State(s) reshored to: | MI |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | sterile fill-finish for pharma |
| What non-domestic negative factors made offshoring less attractive? | Supply chain interruption risk/Natural disaster risk/Political instability |
| What domestic positive factors made reshoring more attractive? | Government Incentives, covid-19 |
| Government Incentive dollar amount: | $90 million |
